Search company, investor...

Predict your next investment

Angel Investor (Individual)

Portfolio Exits

1

About Dan Curran

Dan Curran is the President of 10X Lab and was a former partner at Manifest Digital.

Headquarters Location

Want to inform investors similar to Dan Curran about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Dan Curran News

Takeda touts interim PhIII data of enzyme replacement therapy for rare blood disease

Jan 5, 2023

Lei Lei Wu News Reporter Take­da says in an in­ter­im Phase III analy­sis that its en­zyme re­place­ment ther­a­py re­duced in­stances of low blood platelet count for pa­tients with a rare blood clot dis­or­der known as con­gen­i­tal throm­bot­ic throm­bo­cy­topenic pur­pu­ra (cTTP) com­pared to stan­dard of care plas­ma-based ther­a­pies. Dan Cur­ran Next, it plans to file for au­tho­riza­tion for the drug lat­er this year “broad­ly — so not just in the US and EMA but al­so oth­er ju­ris­dic­tions glob­al­ly,” Take­da head of rare ge­net­ics and hema­tol­ogy Dan Cur­ran told End­points News. Ac­cord­ing to a press re­lease Thurs­day morn­ing, Take­da’s ERT, dubbed TAK-755, re­duced low platelet count events by 60% com­pared to stan­dard of care at the time of in­ter­im analy­sis. The study in­clud­ed around 60 pa­tients, and the in­ter­im analy­sis used da­ta on ado­les­cents and adult pa­tients, but not chil­dren un­der 12. Cur­ran al­so not­ed that the ERT re­duced in­stances of oth­er symp­toms as­so­ci­at­ed with the dis­ease, which man­i­fests in a mul­ti­tude of ways, but said that da­ta would be pre­sent­ed at a fu­ture med­ical con­fer­ence. TTP comes in two forms — con­gen­i­tal and im­mune, in which pa­tients de­vel­op an im­mune re­sponse lat­er in life that trig­gers the dis­ease. TTP pa­tients lack a pro­tein that cleaves Von Wille­brand fac­tor, the glue that sticks platelets to­geth­er to form clots and stop bleed­ing. Take­da’s ERT is a re­com­bi­nant ver­sion of that pro­tein called ADAMTS13. cTTP is ex­ceed­ing­ly rare. Cur­ran es­ti­mat­ed that there are around 300 to 400 cas­es in the US. Pa­tients with the dis­ease ex­pe­ri­ence bleed­ing in or un­der the skin, jaun­dice, ex­treme fa­tigue, vom­it­ing, or oth­er symp­toms, and in the worst cas­es, stroke or seizures. In the study, pa­tients who got Take­da’s ERT al­so ex­pe­ri­enced few­er side ef­fects — 8.9% had ad­verse events on Take­da’s treat­ment com­pared to 47.7% on plas­ma-based in­fu­sions. “Many pa­tients dis­con­tin­ue sup­ple­men­ta­tion with plas­ma-de­rived prod­ucts be­cause of ad­verse events,” Cur­ran not­ed, “so it’s in­cred­i­bly im­por­tant that you have a safe drug that will be used by pa­tients con­tin­u­al­ly.” He lat­er added that, es­pe­cial­ly in the case of cTTP, in which many are di­ag­nosed as chil­dren, it was im­por­tant that pa­tients could use the drug over their en­tire life­time. Like oth­er ERTs, Take­da’s ERT is dosed once every two weeks. Take­da ac­quired TAK-755 from its 2019 buy­out of Shire (which ac­quired the ERT from its 2016 merg­er with ​​Bax­al­ta). Take­da is al­so test­ing the ERT in a Phase II study in iTTP and in a Phase Ib study in sick­le cell dis­ease, both of which Cur­ran said will have da­ta this year. AUTHOR John Carroll Editor & Founder Moderna CEO Stéphane Bancel made it clear early on in their M&A mapping phase that the biotech would be hunting the world for just the right mRNA-related deals to build the company into a global powerhouse. And nothing illustrates that strategy better than the $85 million tuck-in that the biotech is unveiling this morning. Bancel has struck a deal to buy Tokyo-based OriCiro Genomics and its work on cell-free synthesis and amplification of plasmid DNA, building up their set of tech for manufacturing aimed at scaling up production faster and carving weeks out of the process. Keep reading Endpoints with a free subscription Unlock this story instantly and join 154,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP News Reporter A month after the FDA rejected its neuroblastoma drug, the biotech Y-mabs said it will cut 35% of its workforce to save cash and focus on commercializing its lone approved product, Danyelza. The FDA rejected its drug omburtamab on Dec. 2, based on questions about the company’s clinical trial and after an advisory committee voted 16-0 against recommending the drug. The cuts will reduce operating expenses by 28%, and give Y-mabs enough cash to get through the first quarter of 2026. Keep reading Endpoints with a free subscription Unlock this story instantly and join 154,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Paul Schloesser Associate Editor Amgen started off the new year with a bang, joining forces with ADC player Synaffix and agreeing to dole out as high as $2 billion in Synaffix’s largest ADC licensing deal to date. The Dutch biotech — running in the same circles as ADC Therapeutics, Seagen, MacroGenics and Emergence Therapeutics — said Thursday that it secured a licensing deal with Amgen to develop new ADCs. As part of the deal, the Big Pharma gets access to Synaffix’s ADC platforms and technology, starting out with one ADC program. Amgen retains an option to exclusively license four more programs at a later date, but what those programs could be remains under wraps. Read More January 5, 2023 10:31 AM EST Kyle LaHucik Associate Editor GSK is tapping into WuXi Biologics’ T cell-engaging antibodies in a deal worth as much as $1.5 billion , as the UK drugmaker looks to follow suit of others in the T cell-engager field, which includes Amgen’s marketed cancer drug Blincyto. Only $40 million of the GSK deal will initially go to the Shanghai-based contract research and manufacturing giant, but with a biobuck bet above $1 billion, the Big Pharma sees lots of potential. The pact is a boon to WuXi, which suffered a loss of billions in market value after being placed on the US Department of Commerce’s unverified list last February. WuXi was removed from the list last month. Read More ENDPOINTS The year’s crop of US drug approvals won’t rival past vintages for quantity. But of the 45 drugs cleared for use by the FDA in 2022, a third are shaping up to be blockbusters, with high expectations for Lilly’s new diabetes drug, Bristol Myers Squibb’s TYK2 inhibitor and Gilead’s new HIV treatment. The promise of gene therapy became a reality in 2022, with new funding for the FDA to work through its backlog of applications, and three new approvals for bluebird bio (for beta thalassemia and early cerebral adrenoleukodystrophy) and CSL (for hemophilia B). With those approvals came new breakthroughs in price: The $2 million-plus treatment costs are likely to further test the bounds of the commercial market. Premium subscription required Beth Snyder Bulik Senior Editor McKinsey Consulting’s Brian Fox is joining Klick Group to boost its commercialization practice. The 18-year McKinsey veteran headed up the commercial life sciences practice there before joining Klick this week in a bid to drive its go-to-market capabilities with clients. Fox’s expertise spans product launches, sales force management, medical and corporate affairs, market access and clinical development. Klick already offers many of those services to biotech and pharma customers, but is looking to Fox to “turbocharge” those efforts, Klick co-founder and chairman Leerom Segal said. Keep reading Endpoints with a free subscription Unlock this story instantly and join 154,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN

Dan Curran Portfolio Exits

1 Portfolio Exit

Dan Curran has 1 portfolio exit. Their latest portfolio exit was Evolutionize on February 08, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/8/2016

Merger

$99M

1

Date

2/8/2016

Exit

Merger

Companies

Valuation

$99M

Acquirer

Sources

1

Dan Curran Acquisitions

2 Acquisitions

Dan Curran acquired 2 companies. Their latest acquisition was Twist on February 08, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/8/2016

$99M

Acquired

1

2/8/2016

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/8/2016

2/8/2016

Investment Stage

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

Note

Acquired

Subscribe to see more

Sources

1

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.